--- a
+++ b/clusters/9knumclustersv2/clust_155.txt
@@ -0,0 +1,32 @@
+Prior treatment with cluster of differentiation  (CD) agonist or immune checkpoint blockade therapies, anti-programmed-death- (anti-PD-), and anti-PD-L therapeutic antibody
+Prior treatment with CD agonists or immune checkpoint-blockade therapies, including anti-CD, anti-CTLA-, anti-PD-, and anti-PD-L therapeutic antibodies.
+Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, including anti?CTLA-, anti?PD-, and anti?PD-L therapeutic antibodies
+Prior treatment with cluster of differentiation  (CD) agonists or immune checkpoint-blockade therapies, including anti-cluster of differentiation  (anti-CD), anti-cytotoxic T-lymphocyte-associated protein  (anti-CTLA-), anti-programmed death- (anti-PD-), and anti-PD-L therapeutic antibodies
+Prior treatment with cluster of differentiation  (CD) agonists or immune checkpoint blockade therapies, including anti-CD, anti-cytotoxic T-lymphocyte-associated protein  (anti-CTLA-), anti-programmed death- (anti-PD-), and anti-PD-L therapeutic antibodies
+Prior treatment with CD agonists or immune checkpoint blockade therapies, including anti CTLA-, anti-PD and anti-PD-L therapeutic antibodies
+Prior treatment with cluster of differentiation (CD)  (CD) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein  (anti-CTLA-), anti-programmed death- (anti-PD-), or anti-programmed death ligand- (anti-PD-L) therapeutic antibodies
+Prior treatment with CD agonists, anti-PD-, or anti-PD-L therapeutic antibody or pathway targeting agents
+Prior treatment with CD agonists or immune checkpoint blockade therapies, including anti?CTLA-, anti?PD-, and anti?PD-L therapeutic antibodies\r\n* Prior cancer vaccines and cellular immunotherapy are permitted
+Prior therapy with atezolizumab or other immunotherapies including CD agonists, anti-programmed death (PD)-, anti-cytotoxic T-lymphocyte associated protein  (CTLA-), and anti-PD-L therapeutic antibodies
+Prior treatment with a CD agonists, anti-CTLA (except melanoma), anti-PD-, or anti-PD-L therapeutic antibody or pathway targeting agents
+Prior treatment with cluster of differentiation (CD)  agonists or immune checkpoint blockade therapies, or anti-programmed cell death- (PD-) or anti-PD-L therapeutic antibodies
+Prior treatment with CD agonists or immune checkpoint-blockade therapies, including anti-CD, anti-CTLA-, anti-PD-, and anti-PD-L therapeutic antibodies
+Prior treatment with cluster of differentiation (CD) agonists or immune checkpoint blockade therapies, including anti Cytotoxic T Lymphocyte-Associated  (CTLA), anti-programmed death  (PD-), and anti-PD-L therapeutic antibodies
+Prior treatment with immune checkpoint blockade therapies (anti-cytotoxic T-lymphocyte-associated protein  [anti-CTLA-], anti-programmed death- [anti-PD-] or anti-PD-L) or immune agonists (anti-cluster of differentiation [CD], anti-CD, anti-OX)
+Prior treatment with immune checkpoint blockade therapies (anti-cytotoxic T-lymphocyte-associated protein  [CTLA-], anti-programmed death- [PD-] or anti-PD-L) or immune agonists (anti-cluster of differentiation [CD] , anti-CD, anti-OX)
+Prior treatment with CD agonists or immune checkpoint blockade therapies, including anti-CTLA-, anti PD-, and anti PD-L therapeutic antibodies, or any other antibody or drug targeting T-cell costimulation.
+Prior treatment with trastuzumab emtansine, cluster of differentiation  agonists, anti-programmed death-, or anti-PD-L therapeutic antibody or pathway-targeting agents
+Prior treatment with cluster of differentiation  (CD) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein  (anti-CTLA), anti-programmed death- (PD-), or anti-PD-L therapeutic antibodies
+Prior treatment with CD agonists or immune checkpoint blockade therapies, including anti-CTLA, anti-PD-, and anti-PD-L therapeutic antibodies
+Prior treatment with cluster of differentiation (CD)  agonists or immune checkpoint blockade therapies, anti-programmed death- (PD-), and anti-PD-L therapeutic antibody
+Prior treatment with CD agonists or immune checkpoint blockade therapies, including anti-CTLA-, anti-PD-, and anti-PD-L therapeutic antibodies
+Prior treatment with cluster of differentiation  (CD) agonists or immune checkpoint blockade therapies, anti-programmed death- (anti-PD-), and anti-PD-L therapeutic antibody
+CD agonists, immune checkpoint inhibitors including but not limited to CTLA-, anti-PD-, and anti-PD-L therapies
+Prior treatment with cluster of differentiation  (CD) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein  (anti-CTLA-), anti-programmed death- (anti-PD-) or anti-programmed death-ligand  (anti-PD-L) therapeutic antibodies
+Prior treatment with CD agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated antigen  (anti-CTLA-), anti-programmed death- receptor (anti-PD-), and anti-programmed death-ligand  (anti-PD-L) therapeutic antibodies
+Prior treatment with CD agonists, anti-CTLA, anti-PD-, or anti-PD-L therapeutic antibody or pathway-targeting agents
+Prior treatment with cluster of differentiation (CD)  agonists or immune checkpoint blockade therapies, anti-programmed death- (anti-PD-), and anti-PD-L therapeutic antibodies
+Prior treatment with CD agonists, anti- cytotoxic T-lymphocyte-associated protein , anti-PD-, or anti-PDL therapeutic antibody or pathway targeting agents; prior IFN alpha or IL- is allowed following  week washout from treatment end date
+Prior treatment with cluster of differentiation (CD)  agonists or immune checkpoint blockade therapies, anti PD, and anti-PD-L therapeutic antibody
+Prior treatment with CD agonists, anti?PD-, or anti?PD-L therapeutic antibody or pathway-targeting agents
+Prior treatment with CD agonists, anti-CTLA-, anti-programmed death- (PD-), or anti-PD-L therapeutic antibody or pathway-targeting agents